Volume | 926,521 |
|
|||||
News | - | ||||||
Day High | 415.50 | Low High |
|||||
Day Low | 409.245 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Vertex Pharmaceuticals Inc | VRTX | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
410.49 | 409.245 | 415.50 | 411.38 | 407.69 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
24,891 | 926,521 | $ 412.63 | $ 382,310,499 | - | 296.09 - 448.40 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:51:59 | 19 | $ 412.20 | USD |
Vertex Pharmaceuticals (VRTX) Options Flow Summary
Vertex Pharmaceuticals Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
106.26B | 258.31M | - | 9.92B | 3.57B | 13.82 | 29.76 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Vertex Pharmaceuticals News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical VRTX Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 414.00 | 416.705 | 406.97 | 410.79 | 1,170,570 | -2.36 | -0.57% |
1 Month | 420.80 | 437.00 | 406.97 | 418.94 | 1,069,247 | -9.16 | -2.18% |
3 Months | 406.97 | 448.40 | 403.43 | 424.22 | 1,342,570 | 4.67 | 1.15% |
6 Months | 350.37 | 448.40 | 341.85 | 393.71 | 1,357,222 | 61.27 | 17.49% |
1 Year | 296.72 | 448.40 | 296.09 | 369.11 | 1,244,524 | 114.92 | 38.73% |
3 Years | 214.24 | 448.40 | 176.36 | 275.94 | 1,536,841 | 197.40 | 92.14% |
5 Years | 188.01 | 448.40 | 163.681 | 254.99 | 1,552,811 | 223.63 | 118.95% |
Vertex Pharmaceuticals Description
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes. |